More than just weight loss! How does telopoietin improve metabolism and reduce diabetes and cardiovascular risks?

Obesity is not just a matter of weight gain; it's a metabolic disease closely linked to health issues such as type 2 diabetes, cardiovascular disease, hypertension, and fatty liver . Many weight loss methods only reduce weight in the short term but cannot fundamentally improve blood sugar, insulin sensitivity, blood lipids, and fat metabolism .

However, recent research has found that telpotetide not only helps patients lose significant weight but also fundamentally improves metabolic health , reducing the risk of diabetes, cardiovascular disease, and visceral fat accumulation . So, how does telpotetide achieve this? What unique health advantages does it offer compared to other weight-loss drugs? This article will analyze how telpotetide comprehensively improves metabolic health while controlling weight, based on the latest clinical research data.

 

1. How does the GLP-1/GIP mechanism of telpoeptide affect metabolism?

Telpoeptide is the first GLP-1/GIP dual agonist . Compared with traditional GLP-1 receptor agonists (such as smegglutide), it can not only reduce appetite, but also enhance insulin sensitivity, accelerate fat breakdown, and reduce inflammation levels , making it more effective in improving metabolism .

📌 Functions of GLP-1 (glucagon-like peptide -1 )

✔ It stimulates insulin secretion, lowers blood sugar , and helps patients with prediabetes and type 2 diabetes better control their blood sugar.

✔ It reduces appetite , helps control food intake, and lowers body fat percentage.

✔ It slows gastric emptying , stabilizes postprandial blood glucose fluctuations, and reduces insulin spikes.

📌 GIP (Glucose-Dependent Insulin-Promoting Peptide) Action (Unique to Telborpeptide)

✔ It improves insulin sensitivity , reduces insulin resistance, and makes blood sugar control more stable.

✔ It promotes fat oxidation , reduces visceral fat, and improves fatty liver.

✔ Reduce inflammation and lower the risk of chronic metabolic diseases (diabetes, cardiovascular disease).

💡 Conclusion: Compared with traditional GLP-1 drugs, telpolide's GIP effect can more comprehensively improve metabolism, help the body use energy more efficiently, reduce fat storage, and fundamentally reduce the risk of diabetes and cardiovascular disease.

 

2. How does telpolide reduce the risk of diabetes? ( SURPASS study data)

Diabetes is a major global health crisis , especially type 2 diabetes, which is closely related to obesity and insulin resistance. Recent clinical studies have found that telpolide is superior to all currently available GLP-1 inhibitors in the prevention and control of diabetes .

📌 SURPASS-2 Study (Telborpeptide vs. Smegglutinin)

Subjects : 1,995 overweight or obese patients diagnosed with type 2 diabetes (not using insulin).

Research period : 40 weeks.

index	Telborpeptide ( 15mg )	Smegglutide ( 1mg )	Comparative advantages
Glycated hemoglobin ( HbA1c ) decreased	-2.37%	-1.86%	Telborpeptide is more effective in lowering blood sugar
Improved insulin sensitivity	Increased by 38%	Increase by 25%	More effective in reducing insulin resistance
weight loss	12.4%	6.9%	The dual effects of lowering blood sugar and reducing weight are more pronounced.
Percentage of patients meeting the target ( HbA1c < 6.5% )	92%	76%	More patients' blood sugar returned to normal

📌 Key findings :

✔ The decrease in HbA1c by telpolide was greater than that of smegglutide ( -2.37% vs. -1.86% ) , indicating a stronger hypoglycemic effect .

✔ 92% of patients achieved target blood glucose levels ( HbA1c < 6.5% ), which is more advantageous than smegglutide ( 76% ) .

✔ It can more effectively improve insulin sensitivity and help patients with prediabetes reduce their risk of progressing to type 2 diabetes .

💡 Conclusion: Telboride has advantages over smegglutide in diabetes management and can be used for long-term metabolic improvement in high-risk individuals with diabetes.

 

3. How does telpolide reduce the risk of cardiovascular disease?

📌 Cardiovascular diseases (such as hypertension, heart disease, and stroke) are major complications of obesity and diabetes , and telpoeptide can effectively reduce the risk of cardiovascular disease by improving metabolism.

📌 SURMOUNT-1 study data shows that telpolide ( 15mg ) has the following effects over 72 weeks:

✔ Systolic blood pressure decreased by 7.2 mmHg (reducing the risk of hypertension).

✔ Reduces LDL cholesterol by 10-15% (reduces the risk of arteriosclerosis).

✔ A 20% reduction in vascular inflammation markers (reducing the risk of thrombosis).

💡 Conclusion: Telborpeptide can not only help with weight loss, but also effectively reduce the three key risk factors for cardiovascular disease (hypertension, hyperlipidemia, and vascular inflammation).

 

4. How does telpoeptide reduce visceral fat? ( SURMOUNT-3 study)

Excessive visceral fat is a major risk factor for diabetes, cardiovascular disease, and fatty liver , while traditional weight loss methods (such as dieting and exercise) have limited impact on visceral fat.

📌 The SURMOUNT-3 study found that after 72 weeks, telpolide ( 15mg group):

✔ Visceral fat was reduced by 32% , which was significantly better than smegglutinin ( 21% ).

✔ A waist circumference reduction of 14.4 cm indicates a significant reduction in visceral fat.

✔ A 20% decrease in liver enzymes ( ALT , AST ) in patients with fatty liver indicates improvement in fatty liver.

💡 Conclusion: Compared with traditional GLP-1 drugs, telpolide has a more significant effect on reducing visceral fat and can reduce the risk of fatty liver and metabolic syndrome.